Mechanisms regulating enhanced human leukocyte antigen class II-mediated CD4 + T cell recognition of human B-cell lymphoma by resveratrol

References

• American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: ACS; 2010.
   Google Scholar
• Jaglowski SM, Linden E, Termuhlen AM, . Lymphoma in adolescents and young adults. Semin Oncol 2009;36:381–418.
   PubMed Web of Science ®Google Scholar
• Ward EM, Thun MJ, Hannan LM, . Interpreting cancer trends. Ann NY Acad Sci 2006;1076:29–53.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD. Lymphoid malignancies: a decade and a half of dramatic improvements in outcome. Clin Lymphoma Myeloma 2008;8(Suppl. 4):S126–S127.
   PubMedGoogle Scholar
• Cabanillas F. Front-line management of diffuse large B cell lymphoma. Curr Opin Oncol 2010;22:642–645.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. Semin Hematol 2008;45(Suppl. 2):S2–S6.
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71:907–920.
   PubMed Web of Science ®Google Scholar
• Passoni L, Scardino A, Bertazzoli C, . ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood 2002;99:2100–2106.
   PubMed Web of Science ®Google Scholar
• Cartron G, Trappe RU, Solal-Celigny P, . Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res 2011;17:19–30.
   PubMed Web of Science ®Google Scholar
• Lucas DM, Still PC, Perez LB, . Potential of plant-derived natural products in the treatment of leukemia and lymphoma. Curr Drug Targets 2010;11:812–822.
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, . Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218–220.
   PubMed Web of Science ®Google Scholar
• Saiko P, Szakmary A, Jaeger W, . Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 2008;658:68–94.
   PubMed Web of Science ®Google Scholar
• Athar M, Back JH, Kopelovich L, . Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 2009;486:95–102.
   PubMed Web of Science ®Google Scholar
• Athar M, Back JH, Tang X, . Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224:274–283.
   PubMed Web of Science ®Google Scholar
• Delmas D, Lancon A, Colin D, . Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr Drug Targets 2006;7:423–442.
   PubMed Web of Science ®Google Scholar
• Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 2005;16:449–466.
   PubMed Web of Science ®Google Scholar
• Mertens-Talcott SU, Percival SS. Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. Cancer Lett 2005;218:141–151.
   PubMed Web of Science ®Google Scholar
• Cecchinato V, Chiaramonte R, Nizzardo M, . Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol 2007;74:1568–1574.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380–384.
   PubMed Web of Science ®Google Scholar
• Khanna R, Burrows SR, Thomson SA, . Class I processing-defective Burkitt's lymphoma cells are recognized efficiently by CD4 + EBV-specific CTLs. J Immunol 1997;158:3619–3625.
   PubMed Web of Science ®Google Scholar
• Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005;23:975–1028.
   PubMed Web of Science ®Google Scholar
• Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994;12:259–293.
   PubMed Web of Science ®Google Scholar
• Kropshofer H, Vogt AB, Thery C, . A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J 1998;17:2971–2981.
   PubMed Web of Science ®Google Scholar
• Amria S, Cameron C, Stuart R, . Defects in HLA class II antigen presentation in B-cell lymphomas. Leuk Lymphoma 2008;49:353–355.
   PubMed Web of Science ®Google Scholar
• Haque A, Hajiaghamohseni LM, Li P, . Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells. Cell Immunol 2007;249:20–29.
   PubMed Web of Science ®Google Scholar
• Grant BD, Donaldson JG. Pathways and mechanisms of endocytic recycling. Nat Rev Mol Cell Biol 2009;10:597–608.
   PubMed Web of Science ®Google Scholar
• Lazzarino DA, Blier P, Mellman I. The monomeric guanosine triphosphatase rab4 controls an essential step on the pathway of receptor-mediated antigen processing in B cells. J Exp Med 1998;188:1769–1774.
   PubMed Web of Science ®Google Scholar
• Hiraiwa A, Yamanaka K, Kwok WW, . Structural requirements for recognition of the HLA-Dw14 class II epitope: a key HLA determinant associated with rheumatoid arthritis. Proc Natl Acad Sci USA 1990;87:8051–8055.
   PubMed Web of Science ®Google Scholar
• Kovats S, Nepom GT, Coleman M, . Deficient antigen-presenting cell function in multiple genetic complementation groups of type II bare lymphocyte syndrome. J Clin Invest 1995;96:217–223.
   PubMed Web of Science ®Google Scholar
• Haque MA, Hawes JW, Blum JS. Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition. J Immunol 2001;166:4543–4551.
   PubMed Web of Science ®Google Scholar
• Pathak SS, Blum JS. Endocytic recycling is required for the presentation of an exogenous peptide via MHC class II molecules. Traffic 2000;1:561–569.
   PubMed Web of Science ®Google Scholar
• Amria S, Hajiaghamohseni LM, Harbeson C, . HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition. Eur J Immunol 2008;38: 1961–1970.
   PubMed Web of Science ®Google Scholar
• Goldstein OG, Hajiaghamohseni LM, Amria S, . Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma. Cancer Immunol Immunother 2008;57:1461–1470.
   PubMedGoogle Scholar
• Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol Interv 2006;6:36–47.
   PubMed Web of Science ®Google Scholar
• Wu JM, Wang ZR, Hsieh TC, . Mechanism of cardioprotection by resveratrol, a phenolic antioxidant present in red wine (Review). Int J Mol Med 2001;8:3–17.
   PubMed Web of Science ®Google Scholar
• Harikumar KB, Kunnumakkara AB, Sethi G, . Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 2010;127:257–268.
   PubMed Web of Science ®Google Scholar
• Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008;7:1020–1035.
   PubMed Web of Science ®Google Scholar
• Krawczyk M, Leimgruber E, Seguin-Estevez Q, . Expression of RAB4B, a protein governing endocytic recycling, is co-regulated with MHC class II genes. Nucleic Acids Res 2007;35:595–605.
   PubMed Web of Science ®Google Scholar
• Pinet V, Vergelli M, Martin R, . Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 1995;375: 603–606.
   PubMed Web of Science ®Google Scholar
• Lindner R, Unanue ER. Distinct antigen MHC class II complexes generated by separate processing pathways. EMBO J 1996;15: 6910–6920.
   PubMed Web of Science ®Google Scholar
• Aldoss IT, Weisenburger DD, Fu K, . Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncology (Williston Park) 2008;22:1508–1517.
   PubMed Web of Science ®Google Scholar
• Marques FZ, Markus MA, Morris BJ. Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol 2009;41:2125–2128.
   PubMed Web of Science ®Google Scholar
• Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009;11:2851–2897.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Dudley JI, Das DK. Dose-dependency of resveratrol in providing health benefits. Dose Response 2010;8:478–500.
   PubMed Web of Science ®Google Scholar
• Pandey PR, Okuda H, Watabe M, . Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat 2010 Dec 29. [Epub ahead of print].
   Web of Science ®Google Scholar
• Prestwich RJ, Errington F, Hatfield P, . The immune system—is it relevant to cancer development, progression and treatment? Clin Oncol (R Coll Radiol) 2008;20:101–112.
   PubMed Web of Science ®Google Scholar
• God JM, Haque A. Burkitt lymphoma: pathogenesis and immune evasion. J Oncol 2010;2010. pii:516047.
   PubMedGoogle Scholar